Clinical trials: Cardiovascular Events
Transient Ischemic Attack, Non-disabling Stroke
Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT
The objective of the Program of Rehabilitative Exercise and Education to avert Vascular Events after Non-disabling stroke and Transient ischemic attack (PREVENT) Trial is to determine whether the timely delivery of secondary…
- Trial name
- PREVENT (NCT00885456)
- Testing
- PREVENT program, Usual Care
- Where
- 2 sites in Canada
- Volunteers
- 187 people
- Sponsor
- Marilyn MacKay-Lyons
Carotid Artery Disease
CAPTURE 2 Post-Marketing Registry
The purposes of the registry are: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide…
- Trial name
- CAPTURE 2 (NCT00302237)
- Testing
- RX ACCULINK, RX ACCUNET Embolic Protection System
- Where
- United States
- Volunteers
- 6,426 people
- Sponsor
- Abbott Medical Devices
Stroke, Cerebral Infarction
Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients
This is a retrospective, multi-center, real-world study. The researchers plan to include 10,000 cases of ischemic stroke patients using butylphthalide and 10,000 cases of ischemic stroke patients using Edaravone.
- Conditions
- Stroke, Cerebral Infarction, Brain Infarction, Brain Ischemia
- Trial name
- NCT05086874
- Testing
- butylphthalide
- Where
- China
- Volunteers
- 81,292 people
- Sponsor
- Xin Huang
Cardiovascular Death; Major Adverse Cardiovascular Events
2019-nCoV Outbreak and Cardiovascular Diseases
Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last…
- Trial name
- NCT04255940
- Where
- 12 sites in China
- Volunteers
- 12,000 people
- Sponsor
- Qilu Hospital of Shandong University
Unexpected Hospital Mortality, Death, Sudden, Cardiac
Prevention of Serious Adverse Events in Acute Care Hospitals by Afferent Limb and Response Method Intervention - the ALARM Intervention Study.
1. Summary Growing evidence suggests that a significant proportion of in-hospital patient deaths occur after serious adverse events (SAE's).
- Conditions
- Unexpected Hospital Mortality, Death, Sudden, Cardiac, Unplanned Intensive Care Unit Admission
- Trial name
- ALARM (NCT01949025)
- Testing
- ALARM intervention
- Where
- Belgium
- Volunteers
- 69,656 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Fabry Disease
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00074984
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 82 people
- Sponsor
- Genzyme, a Sanofi Company
Sudden Cardiac Arrest
HeartStart FRx Defibrillator Event Registry
This post market clinical follow-up study is a multi-center, non-randomized, unblinded, observational registry of the performance of the FRx Automated external defibrillator (AED) used in conjunction with electrodes with or…
- Trial name
- NCT04250857
- Testing
- HeartStart FRX
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Heartstream US LLC
Cardiac Tumor
Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE)
This study aims to retrospectively and prospectively collect clinical and biological specimen data from patients with cardiac tumors who meet the inclusion and exclusion criteria.
- Trial name
- UNIQUE (NCT06100328)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Congenital Heart Disease, Congestive Heart Failure
The Level of sST2 in Pediatric Heart Failure
Introduction: Suppression of tumorigenicity 2 (ST2) is a receptor member belongs to the Interleukin-1 (IL-1) family. The ligand and soluble versions are its two isoforms.
- Trial name
- NCT06347510
- Testing
- Suppression of tumorigenicity 2 (ST2)
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people
- Sponsor
- Eskisehir Osmangazi University